Literature DB >> 8842454

Differential presynaptic modulation of noradrenaline release in human atrial tissue in normoxia and anoxia.

G Münch1, T Kurz, T Urlbauer, M Seyfarth, G Richardt.   

Abstract

1. Presynaptic modulation of noradrenaline release in human atrial tissue specimens was investigated under normoxic and anoxic conditions. 2. Noradrenaline release was induced by electrical stimulation and release during experimental intervention (S2) was compared with release during a preceding control stimulation (S1). The results were expressed as the geometric means and 95% confidence intervals of the S2/S1 ratio. 3. The alpha 2-adrenoceptor agonist, UK 14304 (0.1 mumol-1) significantly inhibited noradrenaline release, resulting in a S2/S1 ratio of 0.49 (0.40-0.59), and the a 2-adrenoceptor antagonist, yohimbine (1 mumol l-1) increased noradrenaline release (S2/S1 1.83 [1.43-2.35]) during normoxia. Both compounds were ineffective during anoxia. 4. Adenosine (30 mumol-1) inhibited noradrenaline release with a S2/S1 ratio of 0.54 (0.42-0.66). The adenosine antagonist, 8-phenyltheophylline, alone had no effect during normoxia. During anoxia, neither adenosine nor 8-phenyltheophylline altered noradrenaline release. 5. The beta 2-adrenoceptor agonist, terbutaline (1 mumol l-1) increased (1.53 [1.14-2.01]) and the beta-adrenoceptor antagonist, pindolol (1 mumol l-1) suppressed noradrenaline release (0.62 [0.49-0.79]) under normoxic conditions. During anoxia, pindolol significantly inhibited noradrenaline release with a S2/S1 ratio of 0.66 (0.51-0.85), whereas terbutaline did not influence noradrenaline release. 6. Angiotensin II (0.1 mumol l-1 enhanced noradrenaline release resulting in a S2/S1 ratio of 1.44 (1.34-1.54), while the angiotensin II antagonist, losartan (1 mumol l-1) had no effect on noradrenaline release during normoxia. Conversely, angiotensin II did not increase noradrenaline release and losartan significantly inhibited noradrenaline release to a S2/S1 ratio of 0.60 (0.46-0.77) during anoxia. 7. In conclusion, human cardiac tissue possesses presynaptic inhibitory alpha 2-adrenoceptors and adenosine receptors, as well as facilitatory beta 2-adrenoceptors and angiotensin II receptors regulating noradrenaline release under normoxic conditions. During anoxia the responses to alpha 2-adrenoceptors and adenosine receptor stimulation are lost, whereas facilitatory responses to beta 2-adrenoceptors and adenosine II receptor stimulation are maintained and these receptors appear to be maximally stimulated. This differential presynaptic modulation in anoxia may contribute to enhanced sympathetic activity in ischaemia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8842454      PMCID: PMC1909815          DOI: 10.1111/j.1476-5381.1996.tb15614.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

Review 1.  Autonomic neural influences on the dysrhythmias resulting from myocardial infarction.

Authors:  P B Corr; R A Gillis
Journal:  Circ Res       Date:  1978-07       Impact factor: 17.367

2.  The isotope effect of tritium in 3H-noradrenaline.

Authors:  U Trendelenburg; F J Stefano; M Grohmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-06       Impact factor: 3.000

3.  Studies of uptake of the bretylium analogue, iodobenzyltrimethylammonium iodide, by non-primate, monkey and human hearts.

Authors:  E A Carr; M Carroll; R E Counsell; J W Tyson
Journal:  Br J Clin Pharmacol       Date:  1979-11       Impact factor: 4.335

4.  Beta adrenergic and muscarinic cholinergic receptors in canine myocardium. Effects of ischemia.

Authors:  A Mukherjee; T M Wong; L M Buja; R J Lefkowitz; J T Willerson
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

Review 5.  Catecholamine cardiotoxicity.

Authors:  G Rona
Journal:  J Mol Cell Cardiol       Date:  1985-04       Impact factor: 5.000

6.  Adenosine inhibits exocytotic release of endogenous noradrenaline in rat heart: a protective mechanism in early myocardial ischemia.

Authors:  G Richardt; W Waas; R Kranzhöfer; E Mayer; A Schömig
Journal:  Circ Res       Date:  1987-07       Impact factor: 17.367

7.  Release of endogenous catecholamines in the ischemic myocardium of the rat. Part B: Effect of sympathetic nerve stimulation.

Authors:  A M Dart; A Schömig; R Dietz; E Mayer; W Kübler
Journal:  Circ Res       Date:  1984-11       Impact factor: 17.367

8.  Nonexocytotic release of endogenous noradrenaline in the ischemic and anoxic rat heart: mechanism and metabolic requirements.

Authors:  A Schömig; S Fischer; T Kurz; G Richardt; E Schömig
Journal:  Circ Res       Date:  1987-02       Impact factor: 17.367

9.  Compartmentation of cardiac adenine nucleotides and formation of adenosine.

Authors:  J Schrader; E Gerlach
Journal:  Pflugers Arch       Date:  1976-12-28       Impact factor: 3.657

10.  Effect of norepinephrine uptake blockers on norepinephrine kinetics.

Authors:  M Esler; G Jackman; P Leonard; H Skews; A Bobik; P Korner
Journal:  Clin Pharmacol Ther       Date:  1981-01       Impact factor: 6.875

View more
  4 in total

Review 1.  The adrenergic system in pulmonary arterial hypertension: bench to bedside (2013 Grover Conference series).

Authors:  Michael R Bristow; Robert A Quaife
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

2.  Effects of A1-adenosine receptor antagonists on purinergic transmission in the guinea-pig vas deferens in vitro.

Authors:  T A Hardy; J A Brock
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

3.  Contribution of beta-adrenoceptor subtypes to relaxation of colon and oesophagus and pacemaker activity of ureter in wildtype and beta(3)-adrenoceptor knockout mice.

Authors:  J Oostendorp; F Preitner; J Moffatt; M Jimenez; J P Giacobino; P Molenaar; A J Kaumann
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

4.  Norepinephrine release is reduced in cardiac tissue of Type 2 diabetic patients.

Authors:  C Burgdorf; D Richardt; T Kurz; S Adler; A Nötzold; E G Kraatz; H H Sievers; G Richardt
Journal:  Diabetologia       Date:  2003-03-22       Impact factor: 10.122

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.